• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

宫内释放孕酮治疗月经过多

Treatment of menorrhagia with intrauterine release of progesterone.

作者信息

Bergqvist A, Rybo G

出版信息

Br J Obstet Gynaecol. 1983 Mar;90(3):255-8. doi: 10.1111/j.1471-0528.1983.tb08620.x.

DOI:10.1111/j.1471-0528.1983.tb08620.x
PMID:6830732
Abstract

In 12 women with menorrhagia (greater than or equal to 80 ml per menstrual period) a progesterone-releasing device (Progestasert) was inserted. The women were followed by repeated measurements of the blood loss for 12 periods. The menstrual blood loss was significantly reduced after 1 month but the duration of bleeding was somewhat prolonged. Twelve months after insertion the menstrual blood loss amounted to 35% of the blood loss before the insertion. The Progestasert is a valuable treatment for menorrhagia.

摘要

对12名月经过多(每个月经周期出血量大于或等于80毫升)的女性插入了释放孕酮的宫内节育器(普维拉)。对这些女性进行了12个周期的反复失血量测量。1个月后月经量显著减少,但出血时间略有延长。放置12个月后,月经量为放置前失血量的35%。普维拉是治疗月经过多的一种有效方法。

相似文献

1
Treatment of menorrhagia with intrauterine release of progesterone.宫内释放孕酮治疗月经过多
Br J Obstet Gynaecol. 1983 Mar;90(3):255-8. doi: 10.1111/j.1471-0528.1983.tb08620.x.
2
Progesterone/progestogen releasing intrauterine systems versus either placebo or any other medication for heavy menstrual bleeding.含孕激素宫内节育系统与安慰剂或其他药物治疗月经过多的比较
Cochrane Database Syst Rev. 2000(2):CD002126. doi: 10.1002/14651858.CD002126.
3
Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia.左炔诺孕酮宫内节育系统与炔诺酮治疗特发性月经过多的随机对照试验
Br J Obstet Gynaecol. 1998 Jun;105(6):592-8. doi: 10.1111/j.1471-0528.1998.tb10172.x.
4
Long-term suppression of hypermenorrhea by progesterone intrauterine contraceptive devices.宫内孕激素避孕器对月经过多的长期抑制作用。
Am J Obstet Gynecol. 1984 Jul 1;149(5):578-9. doi: 10.1016/0002-9378(84)90043-7.
5
[The role of copper-releasing intrauterine device or levonorgestrel-releasing intrauterine system on uterine bleeding and iron status (prospective study of 8 years)].含铜宫内节育器或左炔诺孕酮宫内缓释系统对子宫出血和铁状态的作用(8年前瞻性研究)
Minerva Ginecol. 2002 Jun;54(3):271-8.
6
Treatment of menorrhagia with a novel 'frameless' intrauterine levonorgestrel-releasing drug delivery system: a pilot study.使用新型“无框架”宫内左炔诺孕酮释放给药系统治疗月经过多:一项试点研究。
Eur J Contracept Reprod Health Care. 2001 Jun;6(2):93-101.
7
The levonorgestrel intrauterine system in the management of menorrhagia.左炔诺孕酮宫内节育系统在月经过多治疗中的应用
Br J Obstet Gynaecol. 1997 May;104(5):614-6. doi: 10.1111/j.1471-0528.1997.tb11542.x.
8
The effect of low-dose 3-keto-desogestrel added to a copper-releasing intrauterine contraceptive device on menstrual blood loss: a double-blind, dose-finding, placebo-controlled study.在含铜宫内节育器中添加低剂量3-酮去氧孕烯对月经量的影响:一项双盲、剂量探索、安慰剂对照研究。
Am J Obstet Gynecol. 2000 Mar;182(3):575-81. doi: 10.1067/mob.2000.104805.
9
Levonorgestrel-releasing intrauterine device in the treatment of menorrhagia.左炔诺孕酮宫内节育器治疗月经过多。
Br J Obstet Gynaecol. 1990 Aug;97(8):690-4. doi: 10.1111/j.1471-0528.1990.tb16240.x.
10
A comparison of flurbiprofen, tranexamic acid, and a levonorgestrel-releasing intrauterine contraceptive device in the treatment of idiopathic menorrhagia.氟比洛芬、氨甲环酸与左炔诺孕酮宫内节育器治疗特发性月经过多的比较。
Am J Obstet Gynecol. 1991 Mar;164(3):879-83. doi: 10.1016/s0002-9378(11)90533-x.

引用本文的文献

1
Progestogen-releasing intrauterine systems for heavy menstrual bleeding.含孕激素的宫内节育系统用于治疗月经过多。
Cochrane Database Syst Rev. 2020 Jun 12;6(6):CD002126. doi: 10.1002/14651858.CD002126.pub4.
2
Benefits and risks of pharmacological agents used for the treatment of menorrhagia.用于治疗月经过多的药物制剂的益处与风险。
Drug Saf. 2004;27(2):75-90. doi: 10.2165/00002018-200427020-00001.
3
Management of menorrhagia.月经过多的管理
BMJ. 1990 Jun 16;300(6739):1537-8. doi: 10.1136/bmj.300.6739.1537.
4
Risk-benefit assessment of drugs used for the treatment of menstrual disorders.
Drug Saf. 1991 May-Jun;6(3):183-91. doi: 10.2165/00002018-199106030-00004.